Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1500

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q4 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

• Analysis of partnership and licensing deals based on clinical stage of development of products.

• Summary of the pharmaceutical deals globally in the five quarters.

• Information on the top deals happened in the pharmaceutical industry.

• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry."

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 8

1.2 List of Figures 12

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q4 2015 16

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q4 2015 16

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q4 2015 19

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q4 2015 20

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2015 21

2.4.1 Allergan and Pfizer to Combine in USD160 Billion Deal 21

2.4.2 Shire Acquires Dyax 22

2.4.3 AstraZeneca Prices Public Offering of Notes for USD6 Billion 23

2.4.4 Sanofi to Enter into Licensing Agreement with Hanmi Pharma 23

2.4.5 AstraZeneca Acquires 55% Stake in Acerta Pharma 24

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q4 2015 25

3.1.1 Top M&A Deals in Q4 2015 26

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q4 2014 – Q4 2015 27

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q4 2015 29

3.2.1 Top Initial Public Offerings in Q4 2015 30

3.2.2 Top Secondary Offerings in Q4 2015 31

3.2.3 Top PIPE Deals in Q4 2015 31

3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2014–Q4 2015 31

3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q4 2014 – Q4 2015 32

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q4 2015 34

3.3.1 Top Venture Financing Deals in Q4 2015 35

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 36

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q4 2015 37

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q4 2014 – Q4 2015 38

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2014 – Q4 2015 40

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2014 – Q4 2015 42

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q4 2015 43

3.4.1 Top Private Equity Deals in Q4 2015 44

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q4 2014 – Q4 2015 45

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2015 47

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q4 2015 47

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q4 2014 – Q4 2015 49

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015 51

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q4 2015 52

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q4 2015 53

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 54

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q4 2014 – Q4 2015 56

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q4 2014 – Q4 2015 57

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 59

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q4 2015 61

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q4 2015 61

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 63

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q4 2015 64

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q4 2015 65

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q4 2015 65

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q4 2014 – Q4 2015 66

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 – Q4 2015 68

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 – Q4 2015 70

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q4 2014 – Q4 2015 71

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q4 2014 – Q4 2015 73

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 75

6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q4 2014 – Q4 2015 75

6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q4 2014 – Q4 2015 77

6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 – Q4 2015 78

6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 – Q4 2015 80

6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q4 2014 – Q4 2015 82

6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 – Q4 2015 84

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 86

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q4 2015 86

7.1.1 Oncology – Deals of the Quarter 88

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q4 2015 91

7.2.1 Central Nervous System – Deals of the Quarter 93

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q4 2015 95

7.3.1 Infectious Disease – Deals of the Quarter 97

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q4 2015 99

7.4.1 Immunology – Deals of the Quarter 101

7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q4 2015 104

7.5.1 Metabolic Disorders – Deals of the Quarter 106

7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q4 2015 108

7.6.1 Cardiovascular – Deals of the Quarter 110

7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q4 2015 112

7.7.1 Gastrointestinal – Deals of the Quarter 114

7.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q4 2015 116

7.8.1 Hematological Disorders – Deals of the Quarter 117

7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q4 2015 119

7.9.1 Respiratory – Deals of the Quarter 120

7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q4 2015 122

7.10.1 Dermatology – Deals of the Quarter 124

8 Deal Summary by Geography 125

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q4 2015 125

8.1.1 North America – Deals of the Quarter 127

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q4 2015 129

8.2.1 Europe – Deals of the Quarter 131

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q4 2015 133

8.3.1 Asia-Pacific – Deals of the Quarter 135

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q4 2015 136

8.4.1 Rest of the World – Deals of the Quarter 138

9 Pharmaceuticals & Healthcare, Global, Top Advisors 139

9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2014 – Q4 2015 139

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q4 2014 – Q4 2015 141

10 Appendix 143

11 Further Information 145

11.1 Methodology 145

11.2 About GlobalData 146

11.3 Disclosure information 146

11.4 Disclaimer 147

Table

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 18

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q4 2015 20

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q4 2015 21

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 26

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q4 2015 26

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q4 2014 – Q4 2015 28

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 30

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q4 2015 30

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q4 2015 31

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q4 2015 31

Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q4 2014–Q4 2015 31

Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 33

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 35

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q4 2015 35

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q4 2015 37

Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 39

Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 41

Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2014 – Q4 2015 42

Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 44

Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q4 2015 44

Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 46

Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 48

Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 50

Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 52

Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2015 52

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q4 2015 53

Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q4 2015 53

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 55

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 – Q4 2015 58

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 60

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 62

Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 64

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q4 2015 64

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q4 2015 65

Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q4 2015 65

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 67

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q4 2014 – Q4 2015 69

Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 – Q4 2015 72

Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 74

Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 – Q4 2015 76

Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 – Q4 2015 77

Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 – Q4 2015 79

Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q4 2014 – Q4 2015 81

Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 – Q4 2015 83

Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 – Q4 2015 85

Table 46: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 87

Table 47: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 92

Table 48: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 96

Table 49: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 100

Table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 105

Table 51: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 109

Table 52: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 113

Table 53: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 117

Table 54: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 120

Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 123

Table 56: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 126

Table 57: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 130

Table 58: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 134

Table 59: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 137

Table 60: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 140

Table 61: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 142

Table 62: Pharmaceuticals & Healthcare, Deals’ Key Financials, Global Acquisition Deals, Q4 2014-Q4 2015 143

Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 16

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q4 2015 19

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q4 2015 20

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q4 2014 – Q4 2015 25

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q4 2014 – Q4 2015 27

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 29

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q4 2014 – Q4 2015 32

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 34

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q4 2015 36

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q4 2015 37

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 – Q4 2015 38

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 40

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 43

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q4 2014 – Q4 2015 45

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 47

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 49

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 51

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 54

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 – Q4 2015 56

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2014 – Q4 2015 57

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q4 2014 – Q4 2015 59

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 61

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 63

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 66

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 68

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q4 2014 – Q4 2015 70

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q4 2014 – Q4 2015 71

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q4 2014 – Q4 2015 73

Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q4 2014 – Q4 2015 75

Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q4 2014 – Q4 2015 77

Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q4 2014 – Q4 2015 78

Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q4 2014 – Q4 2015 80

Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q4 2014 – Q4 2015 82

Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q4 2014 – Q4 2015 84

Figure 35: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 86

Figure 36: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 91

Figure 37: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 95

Figure 38: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 99

Figure 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 104

Figure 40: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 108

Figure 41: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 112

Figure 42: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 116

Figure 43: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 119

Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 122

Figure 45: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 125

Figure 46: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 129

Figure 47: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 133

Figure 48: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 136

Figure 49: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 139

Figure 50: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2014 – Q4 2015 141

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015 thematic reports
Currency USD
$1,500

Can be used by individual purchaser only

$4,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015 in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q4 2015 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.